Zoetis Inc. (NYSE:ZTS) Shares Purchased by US Bancorp DE

US Bancorp DE boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,819 shares of the company’s stock after acquiring an additional 637 shares during the period. US Bancorp DE’s holdings in Zoetis were worth $29,665,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ZTS. Congress Asset Management Co. lifted its stake in Zoetis by 0.4% in the 3rd quarter. Congress Asset Management Co. now owns 689,804 shares of the company’s stock valued at $134,774,000 after buying an additional 3,072 shares in the last quarter. Catalyst Financial Partners LLC lifted its position in shares of Zoetis by 3.6% in the third quarter. Catalyst Financial Partners LLC now owns 2,247 shares of the company’s stock valued at $439,000 after acquiring an additional 78 shares in the last quarter. Financial Advocates Investment Management boosted its stake in shares of Zoetis by 6.2% during the third quarter. Financial Advocates Investment Management now owns 3,451 shares of the company’s stock valued at $674,000 after acquiring an additional 200 shares during the last quarter. Cornerstone Wealth Group LLC increased its position in Zoetis by 4.9% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,019 shares of the company’s stock worth $394,000 after purchasing an additional 95 shares in the last quarter. Finally, Oak Harvest Investment Services raised its stake in Zoetis by 16.8% in the 3rd quarter. Oak Harvest Investment Services now owns 11,685 shares of the company’s stock valued at $2,283,000 after purchasing an additional 1,681 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $181.95 on Friday. The business’s 50-day simple moving average is $188.97 and its 200-day simple moving average is $178.51. The firm has a market capitalization of $82.43 billion, a P/E ratio of 35.61, a P/E/G ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the previous year, the company posted $1.41 earnings per share. Zoetis’s revenue was up 8.3% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is presently 33.86%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.